Hand Swelling and Other Non-Raynaud Phenomenon Symptoms as the Initial Presentation of Systemic Sclerosis: Prevalence and Clinical Associations in Two US Cohorts
- PMID: 40386907
- PMCID: PMC12353935
- DOI: 10.1002/art.43237
Hand Swelling and Other Non-Raynaud Phenomenon Symptoms as the Initial Presentation of Systemic Sclerosis: Prevalence and Clinical Associations in Two US Cohorts
Abstract
Objective: Raynaud phenomenon (RP) is often the initial clinical manifestation of systemic sclerosis (SSc), but some patients develop other manifestations first. To help elucidate the diversity of SSc presentation in its early stages, we describe the initial clinical manifestations and antinuclear antibody (ANA) profiles of patients in two early SSc cohorts.
Methods: All patient data in the Genetics vs Environment in Scleroderma Outcomes Study (GENISOS) and Collaborative National Quality and Efficacy Registry (CONQUER) cohorts were reviewed. Both studies enrolled patients within five years of the first non-RP symptom.
Results: In GENISOS and CONQUER, respectively, 194 (44.2%) of 439 and 292 (31.1%) of 938 patients had a non-RP initial symptom, most commonly puffy fingers/hands. Black patients had a non-RP symptom before RP more commonly than patients in other race and ethnicity categories. Non-RP first patients were more likely than RP first patients to have diffuse cutaneous involvement and joint contractures at enrollment and had a higher prevalence of RNA polymerase III antibody positivity.
Conclusion: In two large US cohorts, >30% of patients began to manifest SSc with puffy fingers/hands or other symptoms, without the "warning sign" of RP as their initial symptom. These patients presented with more severe skin and musculoskeletal disease on average, highlighting the importance of early recognition. The most common autoantibody associated with this presentation was RNA polymerase III. These results should be considered in efforts to recognize SSc in its earliest stages. Puffy fingers/hands, even in the absence of RP, should prompt consideration of early SSc and testing for ANA and SSc-associated autoantibodies, including RNA polymerase III.
© 2025 The Author(s). Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
Conflict of interest statement
Disclosures
The work described in this manuscript was completed when Dr. Victoria Shanmugam was employed by The George Washington University Medical Faculty Associates. The opinions expressed in this manuscript do not reflect the views of the National Institutes of Health, the Department of Health and Human Services, or the United States Government. S. Assassi reports grants paid to his institution from Boehringer Ingelheim, Janssen, and aTyr, as well as consultancy fees from Abbvie, AstraZeneca, aTyr, Boehringer Ingelheim, CSL Behring, Merck, Mitsubishi Tanabe, and TeneoFour. E.J. Bernstein reports grant support from Boehringer Ingelheim, aTYR, Bristol Myers Squibb, and Cabaletta, as well as consultancy fees from Boehringer Ingelheim and Cabaletta. E. Volkmann reports grants from Boehringer Ingelheim, Horizon, Prometheus, Kadmon, and GlaxoSmithKline, as well as consultancy fees from Boehringer Ingelheim, AbbVie, and GlaxoSmithKline.
References
-
- Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354(25):2655–66. - PubMed
-
- Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016;4(9):708–19. doi: S2213-2600(16)30152-7 [pii]; 10.1016/S2213-2600(16)30152-7 [doi] - DOI - PMC - PubMed
Grants and funding
- K24 AR080217/AR/NIAMS NIH HHS/United States
- DOD-W81XWH-22-1-0163/U.S. Department of Defense
- Rheumatology Research Foundation
- RO1HL164758/AR/NIAMS NIH HHS/United States
- K23 AR075112/AR/NIAMS NIH HHS/United States
- Scleroderma Research Foundation
- R01AR081280/AR/NIAMS NIH HHS/United States
- R01 HL164758/HL/NHLBI NIH HHS/United States
- R01 AR081280/AR/NIAMS NIH HHS/United States
- DOD-W81XWH-22-1-0162/U.S. Department of Defense
- K08AR081402/AR/NIAMS NIH HHS/United States
- R01 AR073208/AR/NIAMS NIH HHS/United States
- K23AR075112/AR/NIAMS NIH HHS/United States
- K08 AR081402/AR/NIAMS NIH HHS/United States
- K08AR081402/AR/NIAMS NIH HHS/United States
- K23AR075112/AR/NIAMS NIH HHS/United States
- R01AR081280/AR/NIAMS NIH HHS/United States
- RO1HL164758/AR/NIAMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
